IOVA

Insider Trades

Name	Value	Action	Price	Current Price
Kirby Daniel GordonChief Commercial Officer $55k30k shares BuyJun 5, 2025 $1.84 --

News

globenewswire.comIovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australiaglobenewswire.comJun 3

fool.comIovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For?fool.comJun 2

proactiveinvestors.comIovance Biotherapeutics pushes cell therapy platform into solid tumor marketproactiveinvestors.comJun 1

globenewswire.comIovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001globenewswire.comJun 1

Trade IOVA

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.

CEO: Frederick G. Vogt
IPO Date: Oct 15, 2010

Market Data

Open: $3.98
High: $4.05
Low: $3.85
Volume: 17.4M
Avg Volume: 14.1M
52W High: $5.63
52W Low: $1.66

Valuation

Market Cap: $1.4B
Enterprise Value: $1.2B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-336M
Revenue: $264M
Net Income: $-391M
Cash: $163M
Debt: $48M

Events

EarningsAug 6

EPS est. -0.17